The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Jaimin Chung, director of Canon Medical’s interventional X-ray and vascular business unit, explains the technology behind a new combined CT angiography interventional system aimed at neurology, trauma, stroke and pediatrics that recently received 510(k) FDA clearance.

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.

Canon Medical is launching new X-ray advances at the Radiological Society of North America (RSNA) 2025 annual meeting.

SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data.